GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exicure Inc (NAS:XCUR) » Definitions » Net Income (Continuing Operations)

Exicure (Exicure) Net Income (Continuing Operations) : $2.97 Mil (TTM As of Sep. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Exicure Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Exicure's Net Income (Continuing Operations) for the three months ended in Sep. 2023 was $-5.26 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Sep. 2023 was $2.97 Mil.


Exicure Net Income (Continuing Operations) Historical Data

The historical data trend for Exicure's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exicure Net Income (Continuing Operations) Chart

Exicure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Income (Continuing Operations)
Get a 7-Day Free Trial -22.41 -26.30 -24.67 -64.10 -2.58

Exicure Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.16 18.40 -4.41 -5.76 -5.26

Exicure Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Exicure  (NAS:XCUR) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.


Exicure Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Exicure's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.


Exicure (Exicure) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exicure Inc (NAS:XCUR) » Definitions » Net Income (Continuing Operations)
Traded in Other Exchanges
Address
2430 N. Halsted Street, Suite 410, Chicago, IL, USA, 60614
Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.
Executives
Minhee Eom director 2430 N. HALSTED ST., CHICAGO IL 60614
Dongho Lee director 2430 N. HALSTED ST., CHICAGO IL 60614
Hyuk Joon Ko director 2430 N. HALSTED ST., CHICAGO IL 60614
Hojoon Lee director 2430 N. HALSTED ST., CHICAGO IL 60614
Dgp Co., Ltd. 10 percent owner 23, GEURINTEKEU-RO, YEONGGWANG-EUP, YEONGGWANG-GUN, JEOLLANAM-DO M5 57024
Jung Sang Kim director, officer: Chief Executive Officer, CFO 46-31 CHEONGRO 3 GIL, GEUMSUNG-MYEON, UEISUNG-GUN, GYEONGSANGBUK-DO M5 37357
Josh Miller director, officer: Chief Executive Officer, CFO 2430 N. HALSTED ST., CHICAGO IL 60614
Jiyoung Hwang director C/O EXICURE, INC., 2430 N. HALSTED ST., CHICAGO IL 60614
Cheolho Jo director 2430 N. HALSTED ST., CHICAGO IL 60614
Seung Soo Shin director 2430 N. HALSTED ST., CHICAGO IL 60614
Hyukku Lee director 2430 N. HALSTED ST., CHICAGO IL 60614
Sung Uh Kang Paul director 2430 N. HALSTED ST., CHICAGO IL 60614
Changil Ahn director 2430 N. HALSTED ST., CHICAGO IL 60614
Cbi Usa, Inc. 10 percent owner 3000 WESTERN AVENUE, SUITE 400, SEATTLE WA 98121
Bali Muralidhar director C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077

Exicure (Exicure) Headlines

From GuruFocus

Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders

By Business Wire Business Wire 05-27-2022